CAPR Stock — Capricor Therapeutics Inc.: Cash, EV, Pipeline

Share price

$9.06

Market cap

$526.7M

Cash

$237.9M

Enterprise value

$288.8M

Balance sheet

Cash	$237.9M
Debt	$0.0M
Net cash	$237.9M
Enterprise value	$288.8M
Basic shares	58.1M shares
Fully diluted shares	78.3M shares
Fully diluted market cap	$709.1M
Cash per share	$4.09

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CAPR daily closes…

Loading price history…

Pipeline assets

Deramiocel

Phase 3 · Active Modality: cardiosphere-derived cell (CDC) product

Aliases CAP-1002

Partnerships Nippon Shinyaku: Japan Distribution Agreement (2023). U.S. Commercialization and Distribution Agreement (Jan 2022) — disputed, Capricor filed for preliminary injunction May 7, 2026; Europe term sheet expired Apr 1, 2026, not extended

Indications

Duchenne muscular dystrophy (DMD) (Phase 3)

Catalysts

— August 22, 2026

Status note BLA submitted late 2024, Priority Review, PDUFA Aug 31, 2025; CRL received Jul 2025. Type A meeting Aug 2025 aligned regulatory path on additional HOPE-3 Phase 3 data; CRL response submitted (FDA accepted, new PDUFA Aug 22, 2026). HOPE-3 published in The Lancet Jul 2026; Cellular, Tissue and Gene Therapies Advisory Committee voted 3-9 against substantial evidence of effectiveness for cardiomyopathy (Jul 29, 2026); BIMO inspection Jul 2026 (Form 483, one observation). Company plans BLA amendment with 24-month open-label extension data. Mesoblast patent infringement suit filed Jul 16, 2026.

StealthX exosome platform

Preclinical · Active Modality: exosome (extracellular vesicle) delivery platform

Aliases StealthX

Partnerships NIH, NIAID, Johns Hopkins University (research collaborations); Life Technologies/Thermo Fisher (cell line license, Mar 2022); CSMC (Exosomes License Agreement, May 2014)

Indications

Various diseases (therapeutic applications under exploration) (Stage not disclosed)

Status note Platform exploration for targeted RNA, protein and small molecule therapeutics; no clinical candidate stated in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Deramiocel (CAP-1002)
Lead indication	Muscular Dystrophies
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05126758	Phase 3	Active, not recruiting	Sponsor	Capricor Inc.	—	Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic	—
NCT04428476	Phase 2	Active, not recruiting	Sponsor	Capricor Inc.	—	Duchenne Muscular Dystrophy	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Capricor Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	604,215	+76,200	2.38%	2026-08-14
RTW Investments	250,000	no change	0.05%	2026-08-14
ADAR1 Capital Management	90,593	no change	0.10%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CAPR — Capricor Therapeutics Inc.